PU A. Gemelli, Università Cattolica del Sacro Cuore
Welcome,         Profile    Billing    Logout  
 14 Trials 
33 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Koumarianou, Anna
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Recruiting
3
1000
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Pembrolizumab, Placebo
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
09/28
09/29
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
02/26
09/27
KROCUS, NCT05756153: A Study of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Recruiting
1/2
45
Europe
GFH925, Cetuximab
Genfleet Therapeutics (Shanghai) Inc.
Advance Non-small Cell Lung Cancer
03/25
08/25
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
NCT04064359: Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

Recruiting
1
200
Europe, US
OBT076, a CD205-directed antibody-drug conjugate, MEN1309
Oxford BioTherapeutics Ltd
Solid Tumor
12/26
12/27
Fasching, Peter
NeoON, NCT05036005: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label

Recruiting
4
108
Europe
Ontruzant, SB3, Chemotherapy, Pertuzumab
Institut fuer Frauengesundheit, Samsung Bioepis Co., Ltd.
Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer
04/23
07/23
AIRE, NCT05033769: Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer

Recruiting
4
82
Europe
Eribulin Injection [Halaven], Eribulin, Paclitaxel injection, Paclitaxel
Institut fuer Frauengesundheit, Eisai GmbH
Breast Cancer Female, Neoplasm, Breast, Breast Cancer Metastatic
07/23
09/23
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

Recruiting
4
1000
Europe
Ribociclib
Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals
Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer
10/24
10/26
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
02/26
09/27
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
GBG Forschungs GmbH, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruiting
3
1684
Europe
Ribociclib 200Mg Oral Tablet, Kisqali
West German Study Group, Novartis, Genomic Health®, Inc.
Breast Cancer Female
07/27
07/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
COMPRENDO, NCT05033756: Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (

Active, not recruiting
2
11
Europe
Pembrolizumab Injection [Keytruda], Keytruda, Olaparib Oral Tablet [Lynparza], Lynparza
Institut fuer Frauengesundheit, Merck Sharp & Dohme LLC
Malignant Neoplasm of Breast, Breast Cancer
01/25
02/26
COGNITION-GUIDE, NCT05332561: Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer

Recruiting
2
240
Europe
Atezolizumab 1200 mg in 20 ML Injection, Tecentriq, Inavolisib, Ipatasertib, Olaparib, Lynparza, Sacituzumab govitecan, Trodelvy, Trastuzumab/pertuzumab, Phesgo
German Cancer Research Center
Early-stage Breast Cancer
03/30
12/30
KEYNOTE 721, NCT03310957 / 2017-002289-35: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Completed
1/2
186
Europe, US, RoW
ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
09/24
09/24
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
NCT06638307: A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Recruiting
1
124
US
MEN2312, Elacestrant, Orserdu
Stemline Therapeutics, Inc.
Advanced Breast Cancer
10/25
10/26
CLEAR-B, NCT05870813: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer

Recruiting
N/A
3000
Europe
Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals
Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma
12/23
12/23
PRO2, NCT05425550: Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer During Chemotherapy in Combination With HER2-targeted Therapy or Antibody-drug Conjugate Therapy.

Active, not recruiting
N/A
585
Europe
medidux™ app
Palleos Healthcare GmbH, Mobile Health AG
Breast Cancer
09/25
09/25
PräDigt, NCT06962670: Predicting Cancer Risk With Digital and Molecular Markers

Recruiting
N/A
1250
Europe
Biomaterial collection, BayPass mobile application
University of Erlangen-Nürnberg Medical School
Breast Cancer, Lung Cancer, Colorectal Cancer, Gynecologic Cancer
09/25
12/25
PRAEGNANT, NCT02338167: Praegnant Breast Cancer: Early/Advanced/Metastatic

Recruiting
N/A
13500
Europe
Blood sampling
University Hospital Tuebingen
Advanced/Metastatic Breast Cancer, Breast Cancer (Early Breast Cancer)
03/26
03/27
COGNITION, NCT05906407: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer

Recruiting
N/A
2000
Europe
Genomic Profiling / Sequencing
German Cancer Research Center, University Hospital Heidelberg, German Federal Ministry of Education and Research
Early-Stage Breast Cancer, Neoadjuvant Therapy
12/28
12/28
NCT04755829: Breath Test to Predict Breast Cancer and Outcome of Mammography

Not yet recruiting
N/A
1000
Europe
BreathX test for breath VOCs
Menssana Research, Inc., Mount Vernon Cancer Centre, Zuyderland Medical Centre, University of Erlangen-Nürnberg
Breast Cancer, Abnormal Mammogram, Unspecified
03/23
03/23
CATCH, NCT05652569: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer

Recruiting
N/A
5000
Europe
Genomic Profiling / Sequencing
German Cancer Research Center, University Hospital Heidelberg
Metastatic Breast Cancer
12/30
12/30
Hunter, Bradley
ALPHA3, NCT06500273: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Recruiting
2
250
US
cemacabtagene ansegedleucel, cema-cel, ALLO-647, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, Foresight Lymphoma MRD Therapy Selection Test
Allogene Therapeutics, Foresight Diagnostics, Inc.
Large B-cell Lymphoma
08/27
08/31
DSP-5336-101, NCT04988555: A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

Recruiting
1/2
362
Europe, Canada, Japan, US, RoW
Enzomenib, azoles, Venetoclax, Gilteritinib, Azacitidine (AZA)
Sumitomo Pharma America, Inc.
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
04/27
10/27
MPCT-012L, NCT05826535: Study of LYL314 in Aggressive Large B-Cell Lymphoma

Recruiting
1/2
270
US
LYL314, Fludarabine, Cyclophosphamide
Lyell Immunopharma, Inc.
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
08/26
01/28
SNDX-5613-0708, NCT06226571: A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Recruiting
1
76
Europe, US, RoW
SNDX-5613, Chemotherapy Regimen, HiDAC
Syndax Pharmaceuticals
Acute Myeloid Leukemias
02/27
02/27
iinnovate-2, NCT05556616 / 2022-001418-20: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Completed
1
15
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
06/24
06/24
Gennaro, Daniele
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Terminated
1
54
Europe, US, RoW
KIN-3248
Kinnate Biopharma
Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
10/24
10/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Koumarianou, Anna
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Recruiting
3
1000
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Pembrolizumab, Placebo
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
09/28
09/29
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
02/26
09/27
KROCUS, NCT05756153: A Study of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Recruiting
1/2
45
Europe
GFH925, Cetuximab
Genfleet Therapeutics (Shanghai) Inc.
Advance Non-small Cell Lung Cancer
03/25
08/25
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
NCT04064359: Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

Recruiting
1
200
Europe, US
OBT076, a CD205-directed antibody-drug conjugate, MEN1309
Oxford BioTherapeutics Ltd
Solid Tumor
12/26
12/27
Fasching, Peter
NeoON, NCT05036005: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label

Recruiting
4
108
Europe
Ontruzant, SB3, Chemotherapy, Pertuzumab
Institut fuer Frauengesundheit, Samsung Bioepis Co., Ltd.
Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer
04/23
07/23
AIRE, NCT05033769: Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer

Recruiting
4
82
Europe
Eribulin Injection [Halaven], Eribulin, Paclitaxel injection, Paclitaxel
Institut fuer Frauengesundheit, Eisai GmbH
Breast Cancer Female, Neoplasm, Breast, Breast Cancer Metastatic
07/23
09/23
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

Recruiting
4
1000
Europe
Ribociclib
Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals
Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer
10/24
10/26
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
02/26
09/27
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
GBG Forschungs GmbH, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruiting
3
1684
Europe
Ribociclib 200Mg Oral Tablet, Kisqali
West German Study Group, Novartis, Genomic Health®, Inc.
Breast Cancer Female
07/27
07/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
COMPRENDO, NCT05033756: Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (

Active, not recruiting
2
11
Europe
Pembrolizumab Injection [Keytruda], Keytruda, Olaparib Oral Tablet [Lynparza], Lynparza
Institut fuer Frauengesundheit, Merck Sharp & Dohme LLC
Malignant Neoplasm of Breast, Breast Cancer
01/25
02/26
COGNITION-GUIDE, NCT05332561: Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer

Recruiting
2
240
Europe
Atezolizumab 1200 mg in 20 ML Injection, Tecentriq, Inavolisib, Ipatasertib, Olaparib, Lynparza, Sacituzumab govitecan, Trodelvy, Trastuzumab/pertuzumab, Phesgo
German Cancer Research Center
Early-stage Breast Cancer
03/30
12/30
KEYNOTE 721, NCT03310957 / 2017-002289-35: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Completed
1/2
186
Europe, US, RoW
ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
09/24
09/24
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
NCT06638307: A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Recruiting
1
124
US
MEN2312, Elacestrant, Orserdu
Stemline Therapeutics, Inc.
Advanced Breast Cancer
10/25
10/26
CLEAR-B, NCT05870813: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer

Recruiting
N/A
3000
Europe
Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals
Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma
12/23
12/23
PRO2, NCT05425550: Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer During Chemotherapy in Combination With HER2-targeted Therapy or Antibody-drug Conjugate Therapy.

Active, not recruiting
N/A
585
Europe
medidux™ app
Palleos Healthcare GmbH, Mobile Health AG
Breast Cancer
09/25
09/25
PräDigt, NCT06962670: Predicting Cancer Risk With Digital and Molecular Markers

Recruiting
N/A
1250
Europe
Biomaterial collection, BayPass mobile application
University of Erlangen-Nürnberg Medical School
Breast Cancer, Lung Cancer, Colorectal Cancer, Gynecologic Cancer
09/25
12/25
PRAEGNANT, NCT02338167: Praegnant Breast Cancer: Early/Advanced/Metastatic

Recruiting
N/A
13500
Europe
Blood sampling
University Hospital Tuebingen
Advanced/Metastatic Breast Cancer, Breast Cancer (Early Breast Cancer)
03/26
03/27
COGNITION, NCT05906407: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer

Recruiting
N/A
2000
Europe
Genomic Profiling / Sequencing
German Cancer Research Center, University Hospital Heidelberg, German Federal Ministry of Education and Research
Early-Stage Breast Cancer, Neoadjuvant Therapy
12/28
12/28
NCT04755829: Breath Test to Predict Breast Cancer and Outcome of Mammography

Not yet recruiting
N/A
1000
Europe
BreathX test for breath VOCs
Menssana Research, Inc., Mount Vernon Cancer Centre, Zuyderland Medical Centre, University of Erlangen-Nürnberg
Breast Cancer, Abnormal Mammogram, Unspecified
03/23
03/23
CATCH, NCT05652569: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer

Recruiting
N/A
5000
Europe
Genomic Profiling / Sequencing
German Cancer Research Center, University Hospital Heidelberg
Metastatic Breast Cancer
12/30
12/30
Hunter, Bradley
ALPHA3, NCT06500273: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Recruiting
2
250
US
cemacabtagene ansegedleucel, cema-cel, ALLO-647, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, Foresight Lymphoma MRD Therapy Selection Test
Allogene Therapeutics, Foresight Diagnostics, Inc.
Large B-cell Lymphoma
08/27
08/31
DSP-5336-101, NCT04988555: A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

Recruiting
1/2
362
Europe, Canada, Japan, US, RoW
Enzomenib, azoles, Venetoclax, Gilteritinib, Azacitidine (AZA)
Sumitomo Pharma America, Inc.
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
04/27
10/27
MPCT-012L, NCT05826535: Study of LYL314 in Aggressive Large B-Cell Lymphoma

Recruiting
1/2
270
US
LYL314, Fludarabine, Cyclophosphamide
Lyell Immunopharma, Inc.
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
08/26
01/28
SNDX-5613-0708, NCT06226571: A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Recruiting
1
76
Europe, US, RoW
SNDX-5613, Chemotherapy Regimen, HiDAC
Syndax Pharmaceuticals
Acute Myeloid Leukemias
02/27
02/27
iinnovate-2, NCT05556616 / 2022-001418-20: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Completed
1
15
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
06/24
06/24
Gennaro, Daniele
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Terminated
1
54
Europe, US, RoW
KIN-3248
Kinnate Biopharma
Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
10/24
10/24

Download Options